109 related articles for article (PubMed ID: 20828860)
1. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Okamoto I; Takahashi T; Okamoto H; Nakagawa K; Watanabe K; Nakamatsu K; Nishimura Y; Fukuoka M; Yamamoto N
Lung Cancer; 2011 May; 72(2):199-204. PubMed ID: 20828860
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
3. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
4. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Han JY; Kim JY; Lee SH; Yoo NJ; Choi BG
Lung Cancer; 2011 Nov; 74(2):293-9. PubMed ID: 21440951
[TBL] [Abstract][Full Text] [Related]
5. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Wu JY; Wu SG; Yang CH; Chang YL; Chang YC; Hsu YC; Shih JY; Yang PC
Lung Cancer; 2011 May; 72(2):205-12. PubMed ID: 20832137
[TBL] [Abstract][Full Text] [Related]
6. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
7. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y
J Clin Oncol; 2006 Jan; 24(1):64-9. PubMed ID: 16382114
[TBL] [Abstract][Full Text] [Related]
8. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Yang CH; Yu CJ; Shih JY; Chang YC; Hu FC; Tsai MC; Chen KY; Lin ZZ; Huang CJ; Shun CT; Huang CL; Bean J; Cheng AL; Pao W; Yang PC
J Clin Oncol; 2008 Jun; 26(16):2745-53. PubMed ID: 18509184
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Rothschild S; Bucher SE; Bernier J; Aebersold DM; Zouhair A; Ries G; Lombrieser N; Lippuner T; Lütolf UM; Glanzmann C; Ciernik IF
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):126-32. PubMed ID: 20646869
[TBL] [Abstract][Full Text] [Related]
10. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Sugio K; Uramoto H; Onitsuka T; Mizukami M; Ichiki Y; Sugaya M; Yasuda M; Takenoyama M; Oyama T; Hanagiri T; Yasumoto K
Lung Cancer; 2009 Jun; 64(3):314-8. PubMed ID: 18992959
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Kaira K; Naito T; Takahashi T; Ayabe E; Shimoyama R; Kaira R; Ono A; Igawa S; Shukuya T; Murakami H; Tsuya A; Nakamura Y; Endo M; Yamamoto N
Lung Cancer; 2010 Apr; 68(1):99-104. PubMed ID: 19540616
[TBL] [Abstract][Full Text] [Related]
13. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y
Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
Ku GY; Haaland BA; de Lima Lopes G
Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
[TBL] [Abstract][Full Text] [Related]
16. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
18. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Hata A; Katakami N; Yoshioka H; Fujita S; Kunimasa K; Nanjo S; Otsuka K; Kaji R; Tomii K; Iwasaku M; Nishiyama A; Hayashi H; Morita S; Ishida T
Lung Cancer; 2011 Nov; 74(2):268-73. PubMed ID: 21529987
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
